Toll Free: 1-888-928-9744

Epidermolysis Bullosa Global Clinical Trials Review, H1, 2016

Published: May 31, 2016 | Pages: 57 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Epidermolysis Bullosa Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Epidermolysis Bullosa Global Clinical Trials Review, H1, 2016" provides an overview of Epidermolysis Bullosa clinical trials scenario. This report provides top line data relating to the clinical trials on Epidermolysis Bullosa. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 Report Guidance 4 Clinical Trials by Region 5 Clinical Trials and Average Enrollment by Country 6 Top Countries Contributing to Clinical Trials in Asia-Pacific 8 Top Five Countries Contributing to Clinical Trials in Europe 9 Top Countries Contributing to Clinical Trials in North America 10 Top Countries Contributing to Clinical Trials in Middle East and Africa 11 Clinical Trials by G7 Countries: Proportion of Epidermolysis Bullosa to Dermatology Clinical Trials 12 Clinical Trials by Phase in G7 Countries 13 Clinical Trials in G7 Countries by Trial Status 14 Clinical Trials by Phase 15 In Progress Trials by Phase 16 Clinical Trials by Trial Status 17 Clinical Trials by End Point Status 18 Subjects Recruited Over a Period of Time 19 Clinical Trials by Sponsor Type 20 Prominent Sponsors 21 Top Companies Participating in Epidermolysis Bullosa Therapeutics Clinical Trials 22 Prominent Drugs 24 Clinical Trial Profile Snapshots 25 Appendix 54 Abbreviations 54 Definitions 54 Research Methodology 55 Secondary Research 55 About GlobalData 56 Contact Us 56 Disclaimer 56 Source 57
List of Tables
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Region, 2016* 5 Epidermolysis Bullosa Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6 Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7 Epidermolysis Bullosa Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 8 Epidermolysis Bullosa Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 9 Epidermolysis Bullosa Therapeutics Clinical Trials, North America, Top Countries, 2016* 10 Epidermolysis Bullosa Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 11 Proportion of Epidermolysis Bullosa to Dermatology Clinical Trials, G7 Countries (%), 2016* 12 Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 13 Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 14 Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Phase, 2016* 15 Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 16 Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Trial Status, 2016* 17 Epidermolysis Bullosa Therapeutics Clinical Trials, Global, by End Point Status, 2016* 18 Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 19 Epidermolysis Bullosa Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 20 Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 21 Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 23 Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 24


List of Figures
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Region (%), 2016* 5 Epidermolysis Bullosa Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6 Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7 Epidermolysis Bullosa Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 8 Epidermolysis Bullosa Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 9 Epidermolysis Bullosa Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 10 Epidermolysis Bullosa Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 11 Proportion of Epidermolysis Bullosa to Dermatology Clinical Trials, G7 Countries (%), 2016* 12 Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 13 Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 14 Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Phase (%), 2016* 15 Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 16 Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Trial Status, 2016* 17 Epidermolysis Bullosa Therapeutics Clinical Trials, Global, by End Point Status, 2016* 18 Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 19 Epidermolysis Bullosa Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 20 Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 21 Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 22 Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 24 GlobalData Methodology 55

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energ

Read More...

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify